Venture Investors

Venture Investors is a Wisconsin-based private equity firm founded in 1982, specializing in seed and early-stage investments in biotech and technology-enabled healthcare companies across the United States. With over $200 million in assets under management, the firm focuses on turning innovation into health by targeting and investing in extraordinary ideas that shape the future of health and wellness. Located in the Midwest with access to renowned research universities, Venture Investors seeks to fuel the future of healthcare by identifying and supporting the next big advancements in the industry. The firm's investment portfolio includes sectors such as agriculture, life sciences, technology, clean tech, and healthcare, with a focus on companies in the Midwest region. Through lead investments and co-investing opportunities, Venture Investors aims to support the growth and development of innovative healthcare technologies and solutions.

James R. Adox

President, MD and Managing Partner

Jim Adox

Executive MD

George Arida

Advisor

David Arnstein

CFO

Martin C. Bear

Member of Advisory Board

Scott Button

MD

John Neis

Executive MD

Weiss, Paul M. K.

MD

107 past transactions

Zystor

Series A in 2004
ZyStor Therapeutics, Inc. is a privately-held biotechnology company developing enzyme replacement therapies for the treatment of lysosomal storage diseases.

NeuMoDx Molecular

Series B in 2014
NeuMoDx Molecular, Inc. operates as a molecular diagnostics company. The company develops solutions for molecular diagnostic (MDx) testing in hospital and clinical reference laboratories. NeuMoDx Molecular, Inc. was formerly known as Molecular Systems Corporation and changed its name to NeuMoDx Molecular, Inc. in April 2013. The company was incorporated in 2012 and is based in Ann Arbor, Michigan. As of September 17, 2020, NeuMoDx Molecular, Inc. operates as a subsidiary of QIAGEN N.V.

Alfalight

Series A in 2000
Alfalight designs and manufactures high-power diode lasers for the industrial, defense, and telecommunications markets. Alfalight's innovative technology is based on advanced aluminum-free active region (ALFA) laser structures, enabling the manufacture of laser diodes with exceptionally high reliability and industry-leading efficiency.

Silatronix

Venture Round in 2015
Silatronix develops organosilicon electrolytes for energy storage devices such as ultracapacitors and lithium-ion batteries. The company's technology combines Dr. West's expertise in organosilicon compounds with that of Dr. Hamers in nanostructured electrodes and electronic properties of materials. It was founded in 2007 and headquartered in Wisconsin, United States.

HistoSonics

Series C in 2020
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.

Thalchemy

Seed Round in 2014
Thalchemy Corp. is engaged in developing neurally-inspired algorithms and accelerators to enable continuous sensory processing in smartphones and other battery-operated devices. Its algorithms mimic the operation of the mammalian thalamus, which serves as the routing, filtering, and preprocessing point for sensory data on its way to the neocortex. The company’s sensory processing solution enables continuous detection of complex spatiotemporal signatures across multiple sensory modalities, including gestures and hot words; extends battery life dramatically for smartphones and other continuous sensing platforms; provides power-optimized voice and gesture-based control for next-generation devic.

Mithridion

Series C in 2011
Mithridion is a biopharmaceutical company that discovers and develops drugs for central nervous system disorders, with an initial focus on Alzheimer's disease and schizophrenia.

Roche NimbleGen

Series D in 2003
Roche NimbleGen provides products and services to the life science research market. The company offers SeqCap EZ system, a solution-based capture system that enables enrichment of exome in a single test tube; SeqCap EZ library that covers exome designs, gene panels, and custom content designs; and SeqCap EZ reagents to maximize workflow and order different reagent needs. It also provides SeqCap Epi, an enrichment system that includes a set of target enrichment tools for DNA methylation assessment at single-base resolution, as well as offers SeqCap Epi kits and reagents. The company provides a set of preparation and adapter kits for library construction including SignalMap, a software product for browsing of genomic tracks; and NimbleDesign, an online tool that enables users to design SeqCap EZ choice libraries. It offers DNA microarray products and services for CGH, ChIP-chip, DNA methylation, AccuSNP, CGS, instruments, sequence capture arrays, gene expression microarrays, and their associated workflows. The company also provides online technical and instruction support services. Roche NimbleGen was founded in 1999 and is headquartered in Madison, Wisconsin. As of August 8, 2007, Roche NimbleGen operates as a subsidiary of Roche Holding AG.

Chromatin

Venture Round in 2006
Chromatin is a biotech company developing and marketing innovative technologies and products that benefit the agricultural, energy, chemical, nutritional, and pharmaceutical sectors. Chromatin is unlocking the potential of plants to produce greater value and meaningful products for consumers, growers, seed producers, and bioprocessors. Chromatin is commercializing solutions that proactively address key societal challenges such as improving agricultural productivity and increasing renewable energy resources.

Elucent Medical

Series A in 2017
Elucent Medical is a new idea in breast cancer treatment that exists to bring better healthcare ideas to light through the collective efforts of proven entrepreneurs in medicine, technology, and business. Its aim is to raise the bar for breast cancer treatment while lowering costs, making procedures accessible and affordable for providers and patients alike. Elucent Medical is based in Madison, W.I.

Aerpio Pharmaceuticals

Venture Round in 2012
Aerpio Pharmaceuticals is a new, clinical-stage biotechnology company focused on the development of novel small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Aerpio was created in a spin-out transaction from Akebia Therapeutics to enable more rapid development of its exciting compounds. It is managed by the same successful team from Akebia, employing a similar outsourced approach to pharmaceutical development. Aerpio Pharmaceuticals was founded in 2011 and is based in Cincinnati, Ohio, United States.

Pattern Insight

Series A in 2008
Pattern Insight brings powerful search and data mining technology to the advanced, real-time analysis of every type of engineering and IT data. Pattern Insight have two products. Log Insight is a Big Data analytics and log management platform for analyzing large amounts of machine-generated data in real time. It is used for operational analytics in traditional data center and cloud environments. Log Insight, together with its team and technology has been acquired by VMware in July 2012. Code Insight is a product that identifies and removes all ‘known’ (previously fixed) defects in source code before it is released. Current customers include Cisco, Intel, Qualcomm, Tellabs and Motorola.

HistoSonics

Series A in 2014
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.

EnsoData

Series A in 2022
EnsoData is a startup that utilizes artificial intelligence to analyze the human body to diagnose health conditions. EnsoData, whose software uses machine learning algorithms to help clinicians score sleep data and diagnose patients with sleep apnea and other disorders, has now realized that dream—and then some. EnsoData's autoscoring algorithm combines AASM scoring best practices with cutting edge machine learning algorithms that learn and adapt to every single patient.

Eximis Surgical

Series A in 2020
Eximis Surgical is developing an enabling technology that allows surgeons to quickly remove large specimens through small incisions. Its technology uses RF energized cutting wires temporarily held in place within a containment bag. It was founded in 2014 and headquartered in Louisville, Colorado.

Invenra

Series B in 2018
Invenra Inc. engages in discovering biologics with a focus on antibodies and their derivatives. Its technology combines the cell-free expression of full-length antibodies and extreme miniaturization, enabling the screening of full-length antibodies in phenotypic assays. The company was founded in 2011 and is based in Madison, Wisconsin.

Akebia Therapeutics

Series A in 2009
Akebia Therapeutics, Inc., a pharmaceutical company, focuses on treatments for ischemia and improvement of vascular disease. It engages in the clinical development of compounds for the treatment of anemia and ischemia-related disorders. The company offers Omacor for hypertriglyceridemia; and Actonel for osteoporosis. Its products include prolyl hydroxylase enzyme and phosphatase enzyme. Akebia Therapeutics, Inc. was founded in 2007 and is based in Cincinnati, Ohio.

Aerpio Pharmaceuticals

Series C in 2014
Aerpio Pharmaceuticals is a new, clinical-stage biotechnology company focused on the development of novel small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Aerpio was created in a spin-out transaction from Akebia Therapeutics to enable more rapid development of its exciting compounds. It is managed by the same successful team from Akebia, employing a similar outsourced approach to pharmaceutical development. Aerpio Pharmaceuticals was founded in 2011 and is based in Cincinnati, Ohio, United States.

Celleration

Series E in 2011
Celleration Inc. develops and commercializes therapeutic ultrasound healing technologies in the United States. It offers MIST Therapy, a noncontact and low frequency ultrasound solution delivered through a saline mist to the wound bed. The company serves patients, medical professionals, and payers. Celleration Inc. was formerly known as Advanced Medical Applications, Inc. The company was founded in 1999 and is based in Eden Prairie, Minnesota. As of May 29, 2015, Celleration, Inc. operates as a subsidiary of Alliqua BioMedical, Inc.

IntraLase Corporation

Venture Round in 2000
IntraLase Corporation is a leader in the first step of LASIK surgery, the most common means of surgical vision correction. They design, develop and market a laser, related software and disposable devices used to create a cut of tissue across the cornea of a patient’s eye, or a corneal flap, which is the first step in LASIK surgery. Their advanced laser technology improves the safety, precision and visual acuity of LASIK surgery by providing a computer-controlled laser solution as an alternative to the traditional method of creating the corneal flap using a hand-held mechanical, metal-bladed device called a microkeratome. They believe their product offering will become the new standard of care for corneal flap creation. As of April 2, 2007, IntraLase Corp. was acquired by Advanced Medical Optics Inc.

Mithridion

Series B in 2009
Mithridion is a biopharmaceutical company that discovers and develops drugs for central nervous system disorders, with an initial focus on Alzheimer's disease and schizophrenia.

Inviragen

Series A in 2009
Inviragen is focused on developing life-saving vaccines to protect against emerging infectious diseases worldwide. Inviragen's lead product is a vaccine to protect against dengue fever, a disease that threatens 2.5 billion people across the globe. Inviragen is also developing a vaccine to protect against West Nile for the North American market, a nasal combination vaccine to protect against both plague and smallpox for biodefense, and a unique vaccine to protect against avian influenza for global markets.

Chromatin

Series A in 2002
Chromatin is a biotech company developing and marketing innovative technologies and products that benefit the agricultural, energy, chemical, nutritional, and pharmaceutical sectors. Chromatin is unlocking the potential of plants to produce greater value and meaningful products for consumers, growers, seed producers, and bioprocessors. Chromatin is commercializing solutions that proactively address key societal challenges such as improving agricultural productivity and increasing renewable energy resources.

HealthMyne

Venture Round in 2017
HealthMyne, Inc., a healthcare informatics company, provides novel search, analytics, and imaging solutions to healthcare enterprises. It focuses on providing solutions to cancer care providers. The company’s smart imaging solutions deliver clinical decision support and quality assurance services to reduce diagnostic errors and increase clinical collaboration. Its technology provides physicians with tumor image manipulation, and EHR and image repository search capabilities for diagnosing and treating similar cases. HealthMyne, Inc. was founded in 2013 and is based in Madison, Wisconsin.
Tissue Regeneration Systems Inc. is a start-up medical device company that commercializes a skeletal reconstruction and bone regeneration technology platform licensed from the Universities of Michigan and Wisconsin. Its technology platform is suited for various clinical applications in craniomaxillofacial surgery, orthopedic surgery, spine fusion surgery, and bone growth factor delivery markets. The company was incorporated in 2005 and is based in Plymouth, Michigan with an additional office in Kirkland, Washington. It has a research facility in Ann Arbor, Michigan.

Corona Optical Systems

Series A in 2001
Corona Optical Systems is a Midwest-based high-technology company with headquarters in Lombard, Illinois. Additional facilities are located in Eau Claire, Wisconsin and San Jose, California. Corona's key technologies focus on high-speed optoelectronic components and subsystems for carrier-class equipment. Founded in February 2000, Corona is a privately held, venture capital funded corporation. Following an initial angel round, Corona completed its first institutional investment round in March 2001. Funds raised in this Series A round totaled $12.4 Million. Led by Intel Capital, this round included Chicago based venture capital firm KB Partners, Madison, Wisconsin based Venture Investors and the Geometry Group of New York City.

Celleration

Series B in 2002
Celleration Inc. develops and commercializes therapeutic ultrasound healing technologies in the United States. It offers MIST Therapy, a noncontact and low frequency ultrasound solution delivered through a saline mist to the wound bed. The company serves patients, medical professionals, and payers. Celleration Inc. was formerly known as Advanced Medical Applications, Inc. The company was founded in 1999 and is based in Eden Prairie, Minnesota. As of May 29, 2015, Celleration, Inc. operates as a subsidiary of Alliqua BioMedical, Inc.

Cellectar Biosciences

Venture Round in 2008
Cellectar Biosciences, a radiopharmaceutical company, designs and develops products to detect, treat, and monitor various human cancers. Its products include 131I-CLR1404, a compound for cancer therapy. The company's product candidates combine lipid-like molecules and phospholipid ethers analogs with radioisotopes to image or destroy malignant cells. Cellectar Biosciences was formerly known as Cellectar, LLC and changed its name in 2008. The company was founded in 2003 and is based in Madison, Wisconsin.

Eximis Surgical

Venture Round in 2018
Eximis Surgical is developing an enabling technology that allows surgeons to quickly remove large specimens through small incisions. Its technology uses RF energized cutting wires temporarily held in place within a containment bag. It was founded in 2014 and headquartered in Louisville, Colorado.

Neurovance

Series A in 2015
Neurovance, Inc., a neuroscience-focused company, focuses on the development and commercialization of therapies for adult and children with attention deficit hyperactivity disorders. The company develops centanafadine, a triple reuptake inhibitor that modulates the activity of norepinephrine dopamine and serotonin in a specific ratio. Neurovance, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts. As of March 31, 2017, Neurovance, Inc. operates as a subsidiary of Otsuka America, Inc..

TAI Diagnostics

Venture Round in 2017
TAI Diagnostics is a biotechnology company focused on providing a non-invasive and highly sensitive diagnostic test to monitor the health of transplanted organs in patients who have received solid organ transplants. The company is committed to bringing life-changing cell-free DNA technology to the transplant surveillance market. It was founded in in 2015 and has its headquarters in the Milwaukee County Research Park adjacent to the Medical College of Wisconsin, Blood Research Institute, and Milwaukee Regional Medical Center.

Deltanoid Pharmaceuticals

Series B in 2007
Deltanoid Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the research, development, and commercialization of therapies for the treatment of renal diseases, osteoporosis, skin diseases, and other targets. It focuses on vitamin D analogs and other compounds to develop selected therapies through early phases of the drug development process. The company’s product includes DP001 for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease receiving hemodialysis. It also develops DP006 for the treatment of acne. The company was founded in 1999 and is based in Madison, Wisconsin.

Virent Energy Systems

Series A in 2006
Virent Energy Systems, Inc. operates as an energy technology company that enables the renewable replacement of fossil fuels. Its BioForming platform technology renewably produces transportation fuels, fuel gases, and various chemicals from fossil fuels. Virent Energy Systems, Inc. has a strategic industrial collaboration with Royal Dutch Shell plc. The company was founded in 2002 and is headquartered in Madison, Wisconsin.

ReShape Medical

Series C in 2012
ReShape Medical Inc. provides a non-surgical weight loss procedure that helps people to lose weight. The company’s ReShape procedure combines two intragastric balloons with a one-year personalized weight loss program to help patients with mild to moderate obesity (BMI 30-40). The company’s ReShape is provided at medical weight loss centers. ReShape Medical Inc. was formerly known as Abdominis, Inc. The company was founded in 2005 and is based in San Clemente, California. As of October 2, 2017, ReShape Medical Inc. operates as a subsidiary of EnteroMedics Inc.

ReShape Medical

Series D in 2015
ReShape Medical Inc. provides a non-surgical weight loss procedure that helps people to lose weight. The company’s ReShape procedure combines two intragastric balloons with a one-year personalized weight loss program to help patients with mild to moderate obesity (BMI 30-40). The company’s ReShape is provided at medical weight loss centers. ReShape Medical Inc. was formerly known as Abdominis, Inc. The company was founded in 2005 and is based in San Clemente, California. As of October 2, 2017, ReShape Medical Inc. operates as a subsidiary of EnteroMedics Inc.

EnsoData, Inc.

Private Placement in 2020
EnsoData, Inc. designs and develops machine learning and artificial intelligence software that specializes in the discovery, identification, and actionable reporting of critical to understand disease patterns in temporal health. It offers Sleep Scoring Automation Software that automates the analysis of sleep data to get accurate reading on patients. The company’s software also processes results from clinic and lab tests, monitors chronic disease progression, automated screening for physiological abnormalities, and stratifies at-risk patients and optimizes treatments. It serves sleep medicine doctors and sleep lab technologists. EnsoData, Inc. was founded in 2015 and is based in Madison, Wisconsin.
Tissue Regeneration Systems Inc. is a start-up medical device company that commercializes a skeletal reconstruction and bone regeneration technology platform licensed from the Universities of Michigan and Wisconsin. Its technology platform is suited for various clinical applications in craniomaxillofacial surgery, orthopedic surgery, spine fusion surgery, and bone growth factor delivery markets. The company was incorporated in 2005 and is based in Plymouth, Michigan with an additional office in Kirkland, Washington. It has a research facility in Ann Arbor, Michigan.

Netsocket

Series B in 2013
Netsocket specializes in virtualized, software-defined networking. The company’s flagship Netsocket Virtual Network (NVN) fulfills the promises of SDN and NFV today with powerful, robust automation applications running on a completely virtualized network infrastructure. It was founded in 2006 and headquartered in Plano, Texas.

Mithridion

Series A in 2007
Mithridion is a biopharmaceutical company that discovers and develops drugs for central nervous system disorders, with an initial focus on Alzheimer's disease and schizophrenia.

Promega

Venture Round in 1984
Promega Contributing to the prevention, healing and more. Founded in 1978, which began with the production of enzymes for research, has evolved into a catalog of over 2,000 products for a wide range of applications, including basic research, drug discovery, forensics, paternity testing and diagnosis clinician.

UpTo

Series A in 2014
UpTo is a modern calendar that gives a more complete view of everything coming up that matters without the clutter. It creates a beautiful web calendar for their business or organization. The platform brings calendar to life and allows them to easily add events, without an IT department. Add events through an online account and watch them sync seamlessly across UpTo's mobile app and web calendars. Upto was established in 2011 and is based in Detroit, Michigan, United States.

Health Scholars

Series B in 2020
Health Scholars is a developer of medical simulation training software intended to provide clinical education and training. The company's platform is easy to use and scalable across a health system and effectively manages, delivers and includes interactive training content including the only commercially available as well as clinical VR simulation, enabling users to get cost-effective and richer content experience.

Madison Vaccines

Venture Round in 2017
Madison Vaccines, Inc., a biopharmaceutical company, develops therapeutic plasmid DNA vaccines. It focuses on bone metastases and prostate cancer. The company is based in United States.

FluGen

Venture Round in 2016
FluGen, Inc. develops vaccines that prevents from the diseases caused by influenza viruses. It offers RedeeFlu, a nasal spray vaccine used to protect against influenza and vaccine-loaded intradermal microneedle delivery device. The company was founded in 2007 and is based in Madison, Wisconsin.

FluGen

Series A in 2017
FluGen, Inc. develops vaccines that prevents from the diseases caused by influenza viruses. It offers RedeeFlu, a nasal spray vaccine used to protect against influenza and vaccine-loaded intradermal microneedle delivery device. The company was founded in 2007 and is based in Madison, Wisconsin.
Intersymbol Communications, Inc. develops and manufactures high-speed physical layer components for next generation broadband networking systems. Intersymbol's innovative products enhance the bandwidth and reach while simultaneously reducing the power consumption of broadband networks. This results in a dramatic reduction in deployment cost for next generation network providers.

Roche NimbleGen

Series F in 2004
Roche NimbleGen provides products and services to the life science research market. The company offers SeqCap EZ system, a solution-based capture system that enables enrichment of exome in a single test tube; SeqCap EZ library that covers exome designs, gene panels, and custom content designs; and SeqCap EZ reagents to maximize workflow and order different reagent needs. It also provides SeqCap Epi, an enrichment system that includes a set of target enrichment tools for DNA methylation assessment at single-base resolution, as well as offers SeqCap Epi kits and reagents. The company provides a set of preparation and adapter kits for library construction including SignalMap, a software product for browsing of genomic tracks; and NimbleDesign, an online tool that enables users to design SeqCap EZ choice libraries. It offers DNA microarray products and services for CGH, ChIP-chip, DNA methylation, AccuSNP, CGS, instruments, sequence capture arrays, gene expression microarrays, and their associated workflows. The company also provides online technical and instruction support services. Roche NimbleGen was founded in 1999 and is headquartered in Madison, Wisconsin. As of August 8, 2007, Roche NimbleGen operates as a subsidiary of Roche Holding AG.

Thalchemy

Funding Round in 2015
Thalchemy Corp. is engaged in developing neurally-inspired algorithms and accelerators to enable continuous sensory processing in smartphones and other battery-operated devices. Its algorithms mimic the operation of the mammalian thalamus, which serves as the routing, filtering, and preprocessing point for sensory data on its way to the neocortex. The company’s sensory processing solution enables continuous detection of complex spatiotemporal signatures across multiple sensory modalities, including gestures and hot words; extends battery life dramatically for smartphones and other continuous sensing platforms; provides power-optimized voice and gesture-based control for next-generation devic.

ViaLase

Series C in 2024
ViaLase develops an image-guided femtosecond laser surgical system for the treatment of glaucoma. ViaLase is headquartered in Corona Del Mar, California.

Elephas

Series C in 2023
Disruption in healthcare is accelerated by the need for improved diagnostics, novel pharmaceutical therapies, and the shift to patient-centric solutions. With the mission to tackle the massive oncology dilemma, Elephas is leading the way to change how clinicians treat cancer patients. By harnessing the latest advances in cancer biology, multimodal microscopy, and artificial intelligence, the Elephas platform has the ability to empower clinical decision-making and accelerate drug development.

Visana Health

Seed Round in 2023
Visana Health offers a digital health program focused on improving the quality of life for women who suffer from severe menstrual pain. They've assembled an elite team of endometriosis and pelvic pain experts and patients who know first hand the pain and suffering menstrual pain patients endured. Now they’re on a mission to fix the broken system that is failing women across the globe. Visana Health was founded by Joe Connolly in 2019, who watched his mother suffered from unbearable menstrual pain for two and a half decades.

HistoSonics

Convertible Note in 2022
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.
Delphinus Medical Technologies develops, commercializes, sells, and services the breast cancer screening solutions to hospitals and imaging clinics in the United States and internationally. It commercializes SoftVue, a three-dimensional and tomographic ultrasound imaging and risk assessment device that examines women's breasts for the presence of benign and/or malignant masses, assesses breast cancer risks, diagnoses breast diseases, and monitors therapy. The company was founded in 2009 and is based in Detroit, Michigan.

HistoSonics

Private Placement in 2019
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.

Nextt

Seed Round in 2013
Don’t let plans with friends slip through the cracks! Nextt is a private network for close friends to connect online so they can do more together offline. Nextt simplifies the social planning process, letting you share ideas with friends and iron out the details (the Who, What, When and Where) in private. Use Nextt to get busy living and make quality time with your face-to-face friends a priority again.

EnsoData

Series A in 2020
EnsoData is a startup that utilizes artificial intelligence to analyze the human body to diagnose health conditions. EnsoData, whose software uses machine learning algorithms to help clinicians score sleep data and diagnose patients with sleep apnea and other disorders, has now realized that dream—and then some. EnsoData's autoscoring algorithm combines AASM scoring best practices with cutting edge machine learning algorithms that learn and adapt to every single patient.

Health Scholars

Private Placement in 2019
Health Scholars is a developer of medical simulation training software intended to provide clinical education and training. The company's platform is easy to use and scalable across a health system and effectively manages, delivers and includes interactive training content including the only commercially available as well as clinical VR simulation, enabling users to get cost-effective and richer content experience.

NeuWave Medical

Series B in 2012
NeuWave Medical develops tools that deliver energy to the human body to treat a variety of serious medical conditions. Their company founders are both engineers and physician-scientists which allows determining a clinical need and design solutions that are clinically relevant, effective, and minimally invasive. They strive to make the highest quality devices that are the products of choice for leading physicians and medical centers around the world. The company was founded in 2004 and is headquartered in Madison, Wisconsin.

TomoTherapy

Series A in 1999
TomoTherapy develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy:registered: platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its Hi·Art:registered: treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD:tm: treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile:tm: relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. As of February 2011, there are more than 350 TomoTherapy systems in use in 24 countries worldwide. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

The Pro's Closet

Private Placement in 2020
The Pro's Closet is a re-Commerce company that specializes in the sales of premium pre-owned bicycles and bike manufacturer/distributor overstock. The Pro’s Closet caters to clients wishing to buy and sell both locally and nationwide and offers pickups, consultations, expert advice, and more. The company provides an avenue for anyone (athletes, teams, shops, reps, companies, you) to free up space and put new and used premium products in the hands of people who will give it a second life. The Pro's Closet was founded in 2006 by Nick Martin and is based in Boulder, Colorado.

NeuWave Medical

Series A in 2008
NeuWave Medical develops tools that deliver energy to the human body to treat a variety of serious medical conditions. Their company founders are both engineers and physician-scientists which allows determining a clinical need and design solutions that are clinically relevant, effective, and minimally invasive. They strive to make the highest quality devices that are the products of choice for leading physicians and medical centers around the world. The company was founded in 2004 and is headquartered in Madison, Wisconsin.

SkySpecs

Series C in 2019
SkySpecs automates the inspection, diagnostics, and maintenance of utility scale wind turbines with custom autonomous drones. The company develops an affordable form of energy, through the use of an automated drone inspection service and analytics platform that allows for repeatability, high-quality data, and safer inspections. SkySpecs was founded on 2012 and is based in Ann Arbor, Michigan.

HealthMyne

Private Placement in 2018
HealthMyne, Inc., a healthcare informatics company, provides novel search, analytics, and imaging solutions to healthcare enterprises. It focuses on providing solutions to cancer care providers. The company’s smart imaging solutions deliver clinical decision support and quality assurance services to reduce diagnostic errors and increase clinical collaboration. Its technology provides physicians with tumor image manipulation, and EHR and image repository search capabilities for diagnosing and treating similar cases. HealthMyne, Inc. was founded in 2013 and is based in Madison, Wisconsin.

Euthymics Bioscience

Series A in 2011
Euthymics Bioscience, Inc., a neuroscience-focused-clinical-stage biopharmaceutical company, that develops therapeutics, which help patients with withdrawal symptoms, impulsivity, and cravings. It develops a medicine for alcohol use disorder and smoking cessation. Euthymics Bioscience, Inc. was founded in 2009 and is based in Cambridge, Massachusetts.

Aerpio Pharmaceuticals

Series A in 2013
Aerpio Pharmaceuticals is a new, clinical-stage biotechnology company focused on the development of novel small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Aerpio was created in a spin-out transaction from Akebia Therapeutics to enable more rapid development of its exciting compounds. It is managed by the same successful team from Akebia, employing a similar outsourced approach to pharmaceutical development. Aerpio Pharmaceuticals was founded in 2011 and is based in Cincinnati, Ohio, United States.

NeuWave Medical

Series C in 2015
NeuWave Medical develops tools that deliver energy to the human body to treat a variety of serious medical conditions. Their company founders are both engineers and physician-scientists which allows determining a clinical need and design solutions that are clinically relevant, effective, and minimally invasive. They strive to make the highest quality devices that are the products of choice for leading physicians and medical centers around the world. The company was founded in 2004 and is headquartered in Madison, Wisconsin.

BlueWillow Biologics

Series B in 2009
BlueWillow Biologics is a privately-held biopharmaceutical company focused on developing and commercializing intranasal vaccines, based on its patented nanotechnology platform. The company was originally founded as NanoBio Corporation, a spin-off from the Center for Biologic Nanotechnology at the University of Michigan, and was initially focused on developing nano-scale dermatology applications. Based on promising research generated under several Gates Foundation and NIH contracts, the company underwent a strategic “pivot” in 2016–17 to refocus its nanotechnology platform on the development of intranasal vaccines for respiratory and sexually transmitted diseases.

Roche NimbleGen

Series B in 2001
Roche NimbleGen provides products and services to the life science research market. The company offers SeqCap EZ system, a solution-based capture system that enables enrichment of exome in a single test tube; SeqCap EZ library that covers exome designs, gene panels, and custom content designs; and SeqCap EZ reagents to maximize workflow and order different reagent needs. It also provides SeqCap Epi, an enrichment system that includes a set of target enrichment tools for DNA methylation assessment at single-base resolution, as well as offers SeqCap Epi kits and reagents. The company provides a set of preparation and adapter kits for library construction including SignalMap, a software product for browsing of genomic tracks; and NimbleDesign, an online tool that enables users to design SeqCap EZ choice libraries. It offers DNA microarray products and services for CGH, ChIP-chip, DNA methylation, AccuSNP, CGS, instruments, sequence capture arrays, gene expression microarrays, and their associated workflows. The company also provides online technical and instruction support services. Roche NimbleGen was founded in 1999 and is headquartered in Madison, Wisconsin. As of August 8, 2007, Roche NimbleGen operates as a subsidiary of Roche Holding AG.

Invenra

Private Placement in 2018
Invenra Inc. engages in discovering biologics with a focus on antibodies and their derivatives. Its technology combines the cell-free expression of full-length antibodies and extreme miniaturization, enabling the screening of full-length antibodies in phenotypic assays. The company was founded in 2011 and is based in Madison, Wisconsin.

Juventas Therapeutics

Series B in 2012
Juventas Therapeutics, Inc., a clinical stage biotechnology company, develops non-viral gene therapies that activate natural processes to repair the body. The company focuses on treatment of non-healing wounds in patients with advanced peripheral artery disease. It offers JVS-100, a non-viral gene therapy that expresses stromal cell-derived factor-1 or SDF-1, a naturally occurring signaling protein that has been shown to recruit the body’s own stem cells and promote tissue repair in a range of disease states. Juventas Therapeutics, Inc. was formerly known as AcelleRX Therapeutics, Inc. and changed its name to Juventas Therapeutics, Inc. in April 2009. The company was founded in 2007 and is based in Cleveland, Ohio.
Delphinus Medical Technologies develops, commercializes, sells, and services the breast cancer screening solutions to hospitals and imaging clinics in the United States and internationally. It commercializes SoftVue, a three-dimensional and tomographic ultrasound imaging and risk assessment device that examines women's breasts for the presence of benign and/or malignant masses, assesses breast cancer risks, diagnoses breast diseases, and monitors therapy. The company was founded in 2009 and is based in Detroit, Michigan.

HealthMyne

Series B in 2018
HealthMyne, Inc., a healthcare informatics company, provides novel search, analytics, and imaging solutions to healthcare enterprises. It focuses on providing solutions to cancer care providers. The company’s smart imaging solutions deliver clinical decision support and quality assurance services to reduce diagnostic errors and increase clinical collaboration. Its technology provides physicians with tumor image manipulation, and EHR and image repository search capabilities for diagnosing and treating similar cases. HealthMyne, Inc. was founded in 2013 and is based in Madison, Wisconsin.

ProCertus BioPharm

Venture Round in 2009
ProCertus BioPharm, Inc., an oncology-based pharmaceutical company, develops therapeutics to protect cancer patients from the side effects of radiotherapy and chemotherapy in the United States. Its products include ProDermaCel that protects cancer patients from chemotherapy- and radiotherapy-induced alopecia; DermX, which prevents radiotherapy-induced dermatitis; and OralX that provides protection against chemotherapy- and radiotherapy- induced oral mucositis. ProCertus BioPharm, Inc. was founded in 1997 and is based in Madison, Wisconsin.

FluGen

Series A in 2015
FluGen, Inc. develops vaccines that prevents from the diseases caused by influenza viruses. It offers RedeeFlu, a nasal spray vaccine used to protect against influenza and vaccine-loaded intradermal microneedle delivery device. The company was founded in 2007 and is based in Madison, Wisconsin.

ViaLase

Series A in 2021
ViaLase develops an image-guided femtosecond laser surgical system for the treatment of glaucoma. ViaLase is headquartered in Corona Del Mar, California.

HistoSonics

Private Placement in 2020
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.

Alcon LenSx

Series B in 2009
LensX Lasers is a maker of surgical lasers used to repair cataracts.

BlueWillow Biologics

Series C in 2012
BlueWillow Biologics is a privately-held biopharmaceutical company focused on developing and commercializing intranasal vaccines, based on its patented nanotechnology platform. The company was originally founded as NanoBio Corporation, a spin-off from the Center for Biologic Nanotechnology at the University of Michigan, and was initially focused on developing nano-scale dermatology applications. Based on promising research generated under several Gates Foundation and NIH contracts, the company underwent a strategic “pivot” in 2016–17 to refocus its nanotechnology platform on the development of intranasal vaccines for respiratory and sexually transmitted diseases.

Akebia Therapeutics

Series B in 2011
Akebia Therapeutics, Inc., a pharmaceutical company, focuses on treatments for ischemia and improvement of vascular disease. It engages in the clinical development of compounds for the treatment of anemia and ischemia-related disorders. The company offers Omacor for hypertriglyceridemia; and Actonel for osteoporosis. Its products include prolyl hydroxylase enzyme and phosphatase enzyme. Akebia Therapeutics, Inc. was founded in 2007 and is based in Cincinnati, Ohio.

HistoSonics

Series A in 2010
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.

SkySpecs

Series B in 2018
SkySpecs automates the inspection, diagnostics, and maintenance of utility scale wind turbines with custom autonomous drones. The company develops an affordable form of energy, through the use of an automated drone inspection service and analytics platform that allows for repeatability, high-quality data, and safer inspections. SkySpecs was founded on 2012 and is based in Ann Arbor, Michigan.

Incept

Series A in 2007
Incept BioSystems develops innovative microscale technologies that provide fertility specialists breakthrough capabilities to treat infertility. Our technologies improve the in vitro manipulation, performance, and viability of high-value cells, and our mission is to set the standard for next-generation clinical devices for the Assisted Reproductive Technology (ART) laboratory. Like many specialized cells, human embryos typically behave much differently while in vitro than they would in the body, and this performance gap can limit their developmental growth and potentially their viability. Incept’s System for Microfluidic Assisted Reproductive Technology (SMART) platform is the first to deliver unique control of in vitro cell culture environments so that fertility specialists can offer patients new hope in starting a family.

Silatronix

Venture Round in 2016
Silatronix develops organosilicon electrolytes for energy storage devices such as ultracapacitors and lithium-ion batteries. The company's technology combines Dr. West's expertise in organosilicon compounds with that of Dr. Hamers in nanostructured electrodes and electronic properties of materials. It was founded in 2007 and headquartered in Wisconsin, United States.
Cellectar Biosciences, a radiopharmaceutical company, designs and develops products to detect, treat, and monitor various human cancers. Its products include 131I-CLR1404, a compound for cancer therapy. The company's product candidates combine lipid-like molecules and phospholipid ethers analogs with radioisotopes to image or destroy malignant cells. Cellectar Biosciences was formerly known as Cellectar, LLC and changed its name in 2008. The company was founded in 2003 and is based in Madison, Wisconsin.

SkySpecs

Series A in 2015
SkySpecs automates the inspection, diagnostics, and maintenance of utility scale wind turbines with custom autonomous drones. The company develops an affordable form of energy, through the use of an automated drone inspection service and analytics platform that allows for repeatability, high-quality data, and safer inspections. SkySpecs was founded on 2012 and is based in Ann Arbor, Michigan.

SkySpecs

Private Placement in 2019
SkySpecs automates the inspection, diagnostics, and maintenance of utility scale wind turbines with custom autonomous drones. The company develops an affordable form of energy, through the use of an automated drone inspection service and analytics platform that allows for repeatability, high-quality data, and safer inspections. SkySpecs was founded on 2012 and is based in Ann Arbor, Michigan.

UpTo

Series A in 2013
UpTo is a modern calendar that gives a more complete view of everything coming up that matters without the clutter. It creates a beautiful web calendar for their business or organization. The platform brings calendar to life and allows them to easily add events, without an IT department. Add events through an online account and watch them sync seamlessly across UpTo's mobile app and web calendars. Upto was established in 2011 and is based in Detroit, Michigan, United States.

HistoSonics

Series B in 2017
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.

Akebia Therapeutics

Series C in 2013
Akebia Therapeutics, Inc., a pharmaceutical company, focuses on treatments for ischemia and improvement of vascular disease. It engages in the clinical development of compounds for the treatment of anemia and ischemia-related disorders. The company offers Omacor for hypertriglyceridemia; and Actonel for osteoporosis. Its products include prolyl hydroxylase enzyme and phosphatase enzyme. Akebia Therapeutics, Inc. was founded in 2007 and is based in Cincinnati, Ohio.

Madison Vaccines

Series A in 2014
Madison Vaccines, Inc., a biopharmaceutical company, develops therapeutic plasmid DNA vaccines. It focuses on bone metastases and prostate cancer. The company is based in United States.

Virent Energy Systems

Series B in 2007
Virent Energy Systems, Inc. operates as an energy technology company that enables the renewable replacement of fossil fuels. Its BioForming platform technology renewably produces transportation fuels, fuel gases, and various chemicals from fossil fuels. Virent Energy Systems, Inc. has a strategic industrial collaboration with Royal Dutch Shell plc. The company was founded in 2002 and is headquartered in Madison, Wisconsin.

Silatronix

Funding Round in 2015
Silatronix develops organosilicon electrolytes for energy storage devices such as ultracapacitors and lithium-ion batteries. The company's technology combines Dr. West's expertise in organosilicon compounds with that of Dr. Hamers in nanostructured electrodes and electronic properties of materials. It was founded in 2007 and headquartered in Wisconsin, United States.

Gala Biotech

Venture Round in 2000
Gala Biotech, a Catalent Pharma Solutions Company, was established in 1996 from technology developed at the University of Wisconsin. Located in Middleton, Wisconsin, this rapidly growing company (currently over 40 employees, including 16 PhD’s) has a wide range of capabilities in the fields of molecular biology, vector biology, cell line development, biopharmaceutical manufacturing, protein biochemistry, and quality systems. Gala’s core proprietary technology is GPEx® (Gene Product Expression), a gene insertion/expression technology that allows rapid creation of stable, high-expressing mammalian cell lines for a wide variety of gene products. "Gala" is Greek for milk, and the company's original mission was to produce pharmaceutical proteins in the milk of transgenic cows. The gene insertion technology that Gala developed to generate transgenic animals became the basis of Gala's Gene Product Expression or GPEx® technology for production of recombinant proteins in mammalian cell culture. The genomics revolution has led to the identification of thousands of new genes, and the race is now on to discover, characterize and stably express the protein products of these genes in order to develop new therapeutic proteins. Gala's GPEx® technology, when applied to mammalian cell culture, accelerates this process for its biopharmaceutical partners. Once new therapeutic proteins have been identified for clinical development, production support becomes a major challenge. Gala's mission is to meet this need, and the company has recently established a 43,000 square-foot facility in Middleton, Wisconsin devoted to GPEx®-based cell line development and cGMP-compliant protein production.

Neurovance

Series A in 2014
Neurovance, Inc., a neuroscience-focused company, focuses on the development and commercialization of therapies for adult and children with attention deficit hyperactivity disorders. The company develops centanafadine, a triple reuptake inhibitor that modulates the activity of norepinephrine dopamine and serotonin in a specific ratio. Neurovance, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts. As of March 31, 2017, Neurovance, Inc. operates as a subsidiary of Otsuka America, Inc..

HistoSonics

Series C in 2019
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.

HealthMyne

Venture Round in 2016
HealthMyne, Inc., a healthcare informatics company, provides novel search, analytics, and imaging solutions to healthcare enterprises. It focuses on providing solutions to cancer care providers. The company’s smart imaging solutions deliver clinical decision support and quality assurance services to reduce diagnostic errors and increase clinical collaboration. Its technology provides physicians with tumor image manipulation, and EHR and image repository search capabilities for diagnosing and treating similar cases. HealthMyne, Inc. was founded in 2013 and is based in Madison, Wisconsin.
SoftSwitching Technologies offer the most affordable, effective and scalable power quality and monitoring solutions available on the market. A full array of scalable, battery-free DySC products. I-Sense intelligent sensors that pinpoint time and duration of voltage sags. And Grid Alert™ event notifications—the only global power reporting and notification network in the world.

Madison Vaccines

Series A in 2015
Madison Vaccines, Inc., a biopharmaceutical company, develops therapeutic plasmid DNA vaccines. It focuses on bone metastases and prostate cancer. The company is based in United States.

NERITES

Series A in 2008
At Nerites, they combine world class technology with a management team that has a proven track record of bringing technical innovation to market. The company was founded in 2004 to commercialize a new generation of synthetic biomaterials that can enhance natural tissue repair, reduce complications from traditional devices, and degrade safely when they are no longer needed.